AVROBIO Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2022 / 05:30PM GMT
Michael Eric Ulz - Morgan Stanley, Research Division - Equity Analyst

All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Ulz, one of the biotech analysts here. It's my pleasure to introduce Geoff MacKay, CEO of AVRO Biosciences. Just a reminder, a format for today is a fireside chat. But before we get started, I just need to read a quick disclaimer. For important disclosures, please see the Morgan Stanley Research disclosure website at www.morganstanley.com\research disclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

Questions and Answers:

Michael Eric Ulz - Morgan Stanley, Research Division - Equity Analyst

And with that, Geoff, thanks for joining us today. And maybe just to kick off the Q&A. If you can just talk about your gene therapy platform for people that might not be familiar with it.

Geoff MacKay - AVROBIO, Inc. - Co- Founder, President, CEO & Director

Yes,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot